**Supplementary Information**

**Additional Serologic testing**

Briefly, AviTag-biotinylated receptor binding domain (RBD) proteins from wildtype SARS-CoV-2 and four VOCs (Alpha, Beta, Delta, Gamma) were coated on a MagPlex Avidin microsphere (Luminex) at 5 µg/1 million beads. RBD-coated microspheres (600 beads/antigen) were pre-incubated with serum at a final 1:20 or greater for 1h at 37°C with 800 rpm agitation. After 1 h incubation, 50 µl of phycoerythrin (PE)-conjugated hACE2 (GenScript, 1 µg/ml) were added to the well and incubated for 30 min at 37°C with agitation, followed by two PBS-1% BSA washes. The final readings were acquired using the MAGPIX system.

NCID, n = 130

218 participants

n=76

Unvaccinated

n = 130

Vaccinated

n = 88

NCID, n = 76

SGH, n = 5

NUH n = 3

CGH, n = 2

SKH, n = 2

Supplementary Figure S1: Study flowchart of participant recruitment from each study site: National Centre for Infectious Diseases (NCID), Singapore General Hospital (SGH); National University Hospital (NUH), Changi General Hospital (CGH) and Sengkang Hospital (SKH). Of the 88 vaccinated individuals: 71 had received 2 doses of a mRNA vaccine, 13 had received one dose of a mRNA vaccine and 4 received a non-mRNA vaccine.

|  |  |  |  |
| --- | --- | --- | --- |
|  | Unvaccinatedn = 130 | Vaccinatedn = 84 | *p*-value |
| **Baseline Characteristics** |  |  |  |
| Median age (IQR), years | 39.5 (30-58) | 57 (40.5-64) | <0.001 |
| Male (%) | 67 (51.5) | 33 (39.3) | 0.079 |
| Median Charlson Comorbidity Index (IQR)  | 0 (0-1) | 0 (0-0) | 0.073 |
|  Diabetes mellitus (%) | 28 (21.5) | 9 (10.7) | 0.041 |
|  Hypertension (%) | 28 (21.5) | 18 (21.4) | 0.985 |
|  Hyperlipidaemia (%)  | 32 (24.6) | 25 (29.8) | 0.406 |
|  |  |  |  |
| Median Ct value on diagnosis (IQR) ꭞ  | 18.8 (14.9-22.7) | 19.0(15.2-22.9) | 0.960 |
|  |  |  |  |
| Asymptomatic | 12 (9.2) | 21 (25) | 0.002 |
|  Symptom onset after Diagnosis (%) | 11 (9.3) | 13(20.6) | 0.033 |
|  Median day of illness symptoms start (IQR)  | 2 (2-3) | 2(2-3) | 1.000 |
|  Median Ct values for Symptom Onset After (IQR) | 21.87 (18.8-31.2) | 19.3 (16.6-22.2) | 0.356 |
| Median number of Symptoms Reported (IQR)  | 2 (1-3) | 1 (0-2.5)  | <0.001 |
|  Fever (%) | 96 (73.9) | 39 (46.4)  | <0.001 |
|  Cough (%) | 79 (60.8) | 30(35.7) | <0.001 |
|  Shortness of Breath (%) | 17 (13.1) | 3 (3.6) | 0.028 |
|  Runny Nose (%) | 31 (23.9) | 30 (35.7) | 0.060 |
|  Sore Throat (%) | 43 (33.1) | 22(26.2) | 0.285 |
|  Diarrhoea (%) | 8 (6.2) | 1 (1.2) | 0.093 |
|  |  |  |  |
| Median highest Neutrophil (IQR) × 109/L  | 4.50 (3.07-5.92) | 4.31 (3.58-5.44) | 0.881 |
| Median lowest Lymphocyte (IQR) × 109/L | 0.95 (0.65-1.50) | 1.41 (1-1.85) | <0.001 |
| Median highest C-Reactive Protein (IQR), mg/L | 24.7 (6.9-84.8) | 12.9 (6.1-22.7) | 0.001 |
| Median highest Lactate Dehydrogenase (IQR), U/L | 486 (365-672) | 377.5 (317-432) | <0.001 |
| Median highest Alanine Transferase (IQR), U/L  | 35 (18-74) | 19 (13-34)  | <0.001 |
| **Disease Outcome** |
| Pneumonia (%) | 69 (53.1) | 16(19.0) | <0.001 |
| Supplementary O2 required (%) | 27 (20.8) | 4 (4.8) | 0.001 |
| ICU admission required (%) | 7 (5.4) | 0 | 0.044 |
|  Median days of ICU admission required (IQR)  | 4 (3-9) | - | - |
| Intubation (%) | 2 (1.5) | 0 | 0.521 |
|  Median days of Intubation (IQR)  | 7 (3-11) | - | - |
| COVID-19 specific treatment (%) | 39 (30) | 9 (10.7) | 0.001 |
| Mortality | 2 (1.54) | 0  | 0.521 |

ꭞ Data available only for 122 unvaccinated cases and 77 vaccinated cases

**Supplementary Table ST1:** Baseline characteristics and disease outcomes of unvaccinated versus vaccinated COVID-19 B1.617.2 infected patients who received at least one dose of a mRNA vaccine 14 days prior. Four individuals who received a non-mRNA vaccine were not included.

|  |  |  |
| --- | --- | --- |
|  | **Univariable model** | **Multivariable model** |
|  | **Crude OR (95% CI)** | ***p*-value** | **Adjusted OR (95% CI)** | ***p*-value** |
| Vaccinated  | 0.191(0.064-0.567) | 0.003 | 0.116(0.036-0.373) | <0.001 |
| Age group |  |  |  |  |
| <45 years old | 1 | - | 1 | - |
| 45-64 years old | 5.91(1.81-19.0) | 0.003 | 8.15(2.30-28.9) | 0.001 |
| >64 years old | 12.5(3.81-41.0) | <0.001 | 10.6(2.21-50.6) | 0.003 |
| Male | 0.929(0.432-2.00) | 0.850 | 1.04(0.415-2.59) | 0.940 |
|  |  |  |  |  |
| Diabetes | 5.73(2.49-13.2) | <0.001 | 2.16(0.798-5.84) | 0.130 |
| Hypertension | 4.60(2.06-10.3) | <0.001 | 1.64(0.543-4.94) | 0.381 |
| Presence of other comorbidities, if any  | 4.36(1.91-9.95) | <0.001 | 1.38(0.444-4.31) | 0.576 |

**Supplementary Table ST2:** Odds ratio of candidate risk factors of development of severe COVID-19 for vaccinated COVID-19 B1.617.2 infected patients who received at least one dose of a mRNA vaccine 14 days prior. CI, confidence interval; OR, odds ratio

|  |  |  |
| --- | --- | --- |
|  | **Univariable model** | **Multivariable model** |
|  | **Crude OR (95% CI)** | ***p*-value** | **Adjusted OR (95% CI)** | ***p*-value** |
| Vaccinated  | 0.128(0.059-0.280) | <0.001 | 0.069(0.027-0.180) | <0.001 |
| Age group |  |  |  |  |
| <45 years old | 1 |  | 1 |  |
| 45-64 years old | 2.63(1.35-5.15) | 0.005 | 5.59(2.21-14.2) | <0.001 |
| >64 years old | 3.87(1.78-8.44) | 0.001 | 5.91(1.66-21.1) | 0.006 |
| Male | 1.14(0.644-2.01) | 0.659 | 1.05(0.516-2.14) | 0.892 |
|  |  |  |  |  |
| Diabetes | 6.78(2.87-16.0) | <0.001 | 3.08(1.04-9.08) | 0.041 |
| Hypertension | 2.59(1.30-5.19) | 0.007 | 0.888(0.303-2.59) | 0.828 |
| Presence of other comorbidities, if any  | 4.26(1.94-9.36) | <0.001 | 1.75(0.606-5.05) | 0.301 |

**Supplementary Table ST3:** Odds ratio of candidate risk factors of development of moderately severe COVID-19 for completed mRNA vaccination COVID-19 B1.617.2 infected patients. CI, confidence interval; OR, odds ratio



**Supplementary Figure S2:** Scatterplot of anti-S titres and marginal effect of day of illness by vaccine-breakthrough and unvaccinated groups of COVID-19 B1.617.2 infected patients with 95% confidence intervals from generalized additive mixed models. n=128; vaccine-breakthrough = 698, unvaccinated = 59